No Evidence of Disease Activity: Indirect Comparisons of Oral Therapies for the Treatment of Relapsing–Remitting Multiple Sclerosis

Freedom from disease activity in multiple sclerosis

(2015) E. Havrdova et al.   NEUROLOGY

Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial

(2014) Peter A Calabresi et al.   LANCET NEUROLOGY

Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing–remitting multiple sclerosis: a systematic review and mixed treatment comparison

(2013) Michael Hutchinson et al.   CURRENT MEDICAL RESEARCH AND OPINION

A network meta-analysis of randomized controlled trials for comparing the effectiveness and safety profile of treatments with marketing authorization for relapsing multiple sclerosis

(2013) G. M. Hadjigeorgiou et al.   JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS

Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing–remitting multiple sclerosis: subgroup analyses of the CONFIRM study

(2013) Michael Hutchinson et al.   JOURNAL OF NEUROLOGY

Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study

(2012) Virginia Devonshire et al.   LANCET NEUROLOGY

Pre-specified subgroup analyses of a placebo-controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis

(2012) Aaron E Miller et al.   Multiple Sclerosis Journal

Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis

(2012) Robert J. Fox et al.   NEW ENGLAND JOURNAL OF MEDICINE

Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis

(2012) Ralf Gold et al.   NEW ENGLAND JOURNAL OF MEDICINE

Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool

(2012) Georgia Salanti   Research Synthesis Methods

Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis

(2011) Gavin Giovannoni et al.   LANCET NEUROLOGY

Current Disease-Modifying Treatment of Multiple Sclerosis

(2011) Joy Derwenskus   MOUNT SINAI JOURNAL OF MEDICINE

Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis

(2011) Paul O'Connor et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis

(2010) Gavin Giovannoni et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis

(2010) Ludwig Kappos et al.   NEW ENGLAND JOURNAL OF MEDICINE

Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis

(2010) Jeffrey A. Cohen et al.   NEW ENGLAND JOURNAL OF MEDICINE

No Head-to-Head Trial? Simulate the Missing Arms

(2010) J. Jaime Caro et al.   PHARMACOECONOMICS

Comparative Effectiveness Without Head-to-Head Trials

(2010) James E. Signorovitch et al.   PHARMACOECONOMICS

Healthcare resource utilization following switch or discontinuation in multiple sclerosis patients on disease modifying drugs

(2010) Matthew W. Reynolds et al.   JOURNAL OF MEDICAL ECONOMICS

Meta-analysis of a binary outcome using individual participant data and aggregate data

(2010) Richard D. Riley et al.   Research Synthesis Methods

Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study

(2009) Eva Havrdova et al.   LANCET NEUROLOGY

Meta-analysis of continuous outcomes combining individual patient data and aggregate data

(2007) Richard D. Riley et al.   STATISTICS IN MEDICINE